U.S. FDA Approves Subcutaneous Induction Regimen for SKYRIZI in Adults With Moderately to Severely Active Crohn's Disease

The U.S. Food and Drug Administration (FDA) has approved a subcutaneous induction regimen for AbbVie's SKYRIZI (risankizumab-rzaa) for adults with moderately to severely active Crohn's disease. This approval allows patients to initiate treatment at home using an on-body injector, offering increased flexibility and convenience in treatment initiation while maintaining the drug's established efficacy.